NEWS DETAIL

  • Source : Press Release
  • Date : 2021-06-01
  • Event type : Research
  • Companies : Handok Inc.

Handok Signs New Drug Development Agreement with Deargen to Use Artificial Intelligence

On June 6th, Handok signed an AI-based new drug development agreement with Deargen, a company specializing in the development of artificial intelligence (AI) new drugs.

With the AI new drug development platform developed by Deargen in-home and advanced, Handok quickly discovers candidate materials with high probability of success and accelerates drug development. When Deargen derives candidates for target proteins in a short time with the AI drug development platform DearDTI, Handok conducts further verification studies based on that material. Starting with anticancer drugs, Handok plans to use AI to develop various disease treatments.

In the early years, Deargen announced the effects of Remdessibir's treatment of COVID-19 for the first time in the world using deep learning-based AI technology. In addition, it is the only domestic company to be included in the "TOP 30 LEADING COMPANIES in the FIELD of AI New Testament" selected by DeepPainTelesance (DPI) at the end of 2020 and has been recognized for its technology.

"Handok has been thinking about various ways to develop new drugs with global competitiveness through open innovation, and we expect ai technology to accelerate the development of new drugs with global competitiveness by working with Deargen with excellent AI platform technology, as ai technology can handle vast amounts of data quickly and significantly shorten the development period," said Moon Byung-gon, 2014 Director of the Korea-German Research and Development (R&D) Center.

"We are pleased to have signed this new drug development agreement with Handok, which is at the forefront of developing the domestic bioventure ecosystem, including open innovation, securing new drug development technology, and investing in startups," said Kang Gil-so, "Starting with this agreement, we hope to achieve tangible results and further continue the close partnership with the two companies based on trust."